119 related articles for article (PubMed ID: 16480245)
1. Diabetes associated with atypical antipsychotic treatment may be severe but reversible: case report.
Dibben CR; Kalavalapalli SS; Linnington HE; Hynes FA; Dinneen SF; Adler AI; McKenna PJ
Int J Psychiatry Med; 2005; 35(3):307-11. PubMed ID: 16480245
[TBL] [Abstract][Full Text] [Related]
2. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
[TBL] [Abstract][Full Text] [Related]
5. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.
Potkin SG; Gharabawi GM; Greenspan AJ; Mahmoud R; Kosik-Gonzalez C; Rupnow MF; Bossie CA; Davidson M; Burtea V; Zhu Y; Trivedi JK
Schizophr Res; 2006 Jul; 85(1-3):254-65. PubMed ID: 16797162
[TBL] [Abstract][Full Text] [Related]
6. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.
Leslie DL; Rosenheck RA
Am J Psychiatry; 2004 Sep; 161(9):1709-11. PubMed ID: 15337666
[TBL] [Abstract][Full Text] [Related]
7. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.
Lambert BL; Cunningham FE; Miller DR; Dalack GW; Hur K
Am J Epidemiol; 2006 Oct; 164(7):672-81. PubMed ID: 16943266
[TBL] [Abstract][Full Text] [Related]
8. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
[TBL] [Abstract][Full Text] [Related]
9. Two new atypical antipsychotics: advantages and disadvantages.
Lemon MD
S D J Med; 1998 Aug; 51(8):285-6. PubMed ID: 9724957
[No Abstract] [Full Text] [Related]
10. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone.
Westheide J; Cvetanovska G; Albrecht C; Bliesener N; Cooper-Mahkorn D; Creutz C; Hornung WP; Klingmüller D; Lemke MR; Maier W; Schubert M; Sträter B; Kühn KU
J Sex Med; 2008 Dec; 5(12):2816-26. PubMed ID: 18466271
[TBL] [Abstract][Full Text] [Related]
11. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
12. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.
Ollendorf DA; Joyce AT; Rucker M
MedGenMed; 2004 Jan; 6(1):5. PubMed ID: 15208518
[TBL] [Abstract][Full Text] [Related]
13. [The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Mosolov SN; Kabanov SO
Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):62-9. PubMed ID: 14681970
[No Abstract] [Full Text] [Related]
14. The value of atypical antipsychotics in the treatment of schizophrenia.
Jessen LM
Manag Care; 2002 Jul; 11(7 Suppl):8-12; discussion 12-3. PubMed ID: 12181875
[No Abstract] [Full Text] [Related]
15. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial.
Gharabawi GM; Greenspan A; Rupnow MF; Kosik-Gonzalez C; Bossie CA; Zhu Y; Kalali AH; Awad AG
BMC Psychiatry; 2006 Oct; 6():45. PubMed ID: 17054789
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
18. Atypical antipsychotic medication: a nightmarish problem!
Bretag-Norris R; Alexander J
Aust N Z J Psychiatry; 2012 Sep; 46(9):909. PubMed ID: 22956572
[No Abstract] [Full Text] [Related]
19. Cataracts and quetiapine.
Valibhai F; Phan NB; Still DJ; True J
Am J Psychiatry; 2001 Jun; 158(6):966. PubMed ID: 11384916
[No Abstract] [Full Text] [Related]
20. Thyroid dysfunction during treatment with atypical antipsychotics.
Greenspan A; Gharabawi G; Kwentus J
J Clin Psychiatry; 2005 Oct; 66(10):1334-5. PubMed ID: 16259552
[No Abstract] [Full Text] [Related]
[Next] [New Search]